New On Robinhood

C4 Therapeutics

$38.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.34 (+0.90%) Today
$0.00 (0.00%) As of 9:15 PM UTC after-hours

Why Robinhood?

You can buy or sell CCCC and other stocks, options, and ETFs commission-free!

About CCCC

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA. The listed name for CCCC is C4 Therapeutics, Inc. Common Stock.

CEO
Andrew J. Hirsch
Employees
—
Headquarters
Watertown, Massachusetts
Founded
2015
Market Cap
1.52B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
235.01K
High Today
$39.00
Low Today
$36.57
Open Price
$37.54
Volume
214.74K
52 Week High
$41.40
52 Week Low
$22.40

Collections

CCCC Earnings

-$17.55
-$11.70
-$5.85
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, After Hours

You May Also Like

IR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure